Table 6.
Correspondence between in vitro activity and clinical efficacy in individual tumors
In vitro results | Clinical results | |
---|---|---|
Primary | Carboplatin/taxol | |
S/S | S | |
R/S | S | |
R/R | R | |
R/R | R | |
R/R | R | |
R/R | R | |
Carboplatin | ||
R | R | |
Recurrent | Carboplatin/taxol | |
S/S | S | |
R/S | R | |
S/S | S | |
S/R | R | |
R/R | R | |
R/R | R | |
R/R | R | |
R/R | R | |
R/R | R | |
R/R | R | |
R/R | R | |
Cisplatin/adriamycin | ||
R/R | R | |
S/S | S | |
S/S | S | |
S/S | S | |
R/R | R | |
R/R | R | |
Carboplatin | ||
R | R | |
R | R | |
Carboplatin/gemcitabine | ||
R/R | R | |
R/R | R | |
Carboplatin/taxol/gemcitabine | ||
R/R/R | R | |
R/R/R | R |
S, sensitive; R, resistant